亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

布舍瑞林/buserelin/68630-75-1

 
 
單價(jià) 3.00 / g對(duì)比
銷(xiāo)量 暫無(wú)
發(fā)貨 四川成都市付款后3天內(nèi)
庫(kù)存 1000g起訂1g
品牌 成都云希
過(guò)期 長(zhǎng)期有效
更新 2022-09-19 10:25
 

成都云希化工有限公司

企業(yè)會(huì)員第6年
資料未認(rèn)證
保證金未繳納
詳細(xì)說(shuō)明

布舍瑞林--buserelin

今天介紹布舍瑞林--buserelin

CAS號(hào):68630-75-1

英文名稱:BUSERELIN

英文同詞:Fuset;hoe766;EstoMal;hoe766mp;Itorelin;Suprecur;SupreMon;Buserecur;Suprafact;Suprecur-MP

中文名稱:布舍瑞林

中文同義詞:布舍瑞林醋酸鹽;布賽來(lái)靈醋酸酯;布舍瑞林乙酸鹽;醋酸布舍瑞林 68630-75-1

CBNumber:CB9287695

分子式:C60H86N16O13

分子量:1239.42

MOL File:68630-75-1.mol

我司有藍(lán)銅肽、二肽、三肽、四肽、五肽、六肽、七肽、八肽、九肽、十肽等100多種美容活性肽,是國(guó)內(nèi)專業(yè)、質(zhì)量可靠的美容肽供應(yīng)商-成都云希化工有限公司 歡迎咨詢

舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
云希專注勝肽乙酰基六肽-49/DELISENS 乙酰基六肽-1 乙酰基四肽-2 三肽-10瓜氨酸/核心蛋白聚糖肽 Polypeptide-23 乙酰基六肽-7抗衰多肽 Sh-Decapeptide-7 Oligopeptide-21/寡肽21
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |